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The Symposium of Regenerative Medicine for Patients, organized by the Japanese Society for Regener-
ative Medicine, was held on 28 September 2014 in Tokyo, Japan. The event provided an overview of the
important areas of cell-based medicine, and highlighted the ﬁrst-in-human clinical trial of induced
pluripotent stem cell (iPSC)-derived products. Recent advances in regenerative medicine were also
discussed, especially regarding the use of somatic cells such as chondrocytes, skeletal myocytes and
cardiomyocytes under both the Act on the Safety of Regenerative Medicine, and the Pharmaceuticals,
Medical Devices and Other Therapeutic Products Act.
© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Objectives
The Symposium of Regenerative Medicine for Patients aimed to
promote research in regenerative medicine to the scientiﬁc com-
munity, and inform the general public of the advances being
made, by providing an important forum to discuss key issues and
new research in the ﬁeld. The event offered a valuable platform
for sharing new ideas and the latest developments in basic
research, clinical translation, industrial development and regulato-
ry issues encompassing stem cell biology, cell engineering, tissue
engineering, and regenerative medicine. The symposium played
an important part in our overarching goal to develop suitable treat-
ments for our patients as quickly and safely as we can.
2. Participants
The symposium brought together representatives from
academia, medicine, industry, and government in Japan as well as
many general citizens, with a total of approximately 1200 people
in attendance.
3. Message from Japanese prime minister
Shinzo Abe, Prime Minister of Japan, delivered the opening
address of the event. In his speech, Abe emphasized the importance
of research and development (R&D) of pharmaceuticals andse Society for Regenerative
ative Medicine. Production and homedical devices to treat diseases. He recounted his own personal
experience of ulcerative colitis, which was successfully treated by
a novel drug, and described his hope and optimism for the develop-
ment of new drugs and regenerative medicine therapies in the
future. The prime minister described that Japan is a world leader
in stem cell science and the use of induced pluripotent stem cells
(iPSCs). To further bolster Japan's research capabilities, Abe reaf-
ﬁrmed the Japanese government's decision to commit a budget of
USD$1 billion over 10 years to stem cell science and regenerative
medicine, and the introduction of two important new laws: the
Act on the Safety of Regenerative Medicine, and the Pharmaceuti-
cals, Medical Devices and Other Therapeutic Products Act (PMD
Act). Under these new laws, the development of medical techniques
and devices is expected to accelerate. Prime Minister Abe
concluded his speech with hopes that Japan's innovations and
research will further contribute to the development of medicine
around the world.
4. Interdisciplinary research area between biological science
and engineering
Teruo Okano, President of Japan's Society for Regenerative Med-
icine and Editor-in-Chief of this journal, led a discussion about how
regenerative medicine can be developed through the fusion of bio-
logical science and engineering. He used the example of automobile
manufacture to illustrate his point: automobiles are manufactured
in a series of parts, such as tires, and tires are made from rubber.
Similarly, cells as raw materials are propagated ex vivo, and are
used to generate parts of cell products, such as cardiomyocytessting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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cell processing centers or facilities, just as automobiles are put
together at an assembly plant.
In the early 1990s, Okano and colleagues developed a novel
technique to generate cell sheets by fusing knowledge of both en-
gineering and cell biology [1,2]. Okano described how this cell sheet
technique has been used in clinical studies to treat diseases of the
eyes, esophagus, and joints at Osaka University, Tokyo Women's
Medical University and Tokai University, respectively [3e5], and
noted the important development of transport technology in Japan,
which has made cell products more widely available to patients in
rural areas of Japan. Okano discussed the need for innovations in
high-volume manufacturing to treat larger numbers of patients
and reduce production costs, and how automated devices are
currently being developed by industry to address this need. He
noted that from November 2014, commission of the manufacture
of cell products in Japan will be permitted under the Act on the
Safety of Regenerative Medicine. In addition, early conditional
approval of cell product manufacture will commence under the
Act on the Safety of Regenerative Medicine and PMD Act. Okano
highlighted the importance of collaboration in the areas of biology,
medicine and engineering to accumulate and broaden knowledge,
enhance scientiﬁc and industrial development, and to strengthen
an interdisciplinary approach in regenerative medicine research.
5. First-in-human clinical trial of iPSC-based therapy
Nobel prize-winning stem cell researcher Shinya Yamanaka
gave a keynote lecture at the symposium and celebrated the ﬁrst-
in-human clinical trial using iPSCs led by Masayo Takahashi, a
RIKEN researcher [6e8]. iPSCs are a type of pluripotent stem cell
able to differentiate into multiple cell types such as neuron, hepa-
tocyte, cardiomyocyte and beta cells [9].
Yamanaka described the aim of the Center for iPS Cell Research
and Application (CiRA), where he is based, to start clinical trials us-
ing iPSCs, and examined the challenges involved in this work.
Autologous iPSCs derived from patients are suitable as a means to
avoid immunological rejection; however, it can take six months
to generate iPSCs, differentiate them into target cells, and perform
safety tests. Yamanaka also highlighted the cost of iPSC products,
which can run up to several hundred thousand dollars for just
one person.
In light of these challenges, Shinya Yamanaka talked about
CiRA's plans to prepare a storage bank of iPSCs as raw materials
of cell products fromvolunteers with homozygous HLA types; iPSCs
from 75 people with different homozygous HLAs are considered to
cover 80% of Japanese HLA types [10]. He outlined CiRA's four objec-
tives to be achieved by 2020: (1) to advance iPSC technology and
protect intellectual property; (2) to generate iPSC stock for regener-
ative medicine; (3) to commence a ﬁrst-in-human clinical trial; and
(4) to further drug discovery using patient iPSCs. In closing, Shinya
Yamanaka stressed the need to reduce the transformation possibil-
ity of iPSC-derived products during manufacturing and after im-
plantation, and drew attention to the fact that patients will be
most affected by this drawback.
Next, Masayo Takahashi presented to the symposium details
from her team's clinical trial of iPSCs in a patient with age-related
macular degeneration. Macular degeneration is an intractable eye
disease characterized by abnormal blood vessels growing beneath
the retina. These new blood vessels leak ﬂuid or blood that dam-
ages retinal pigmented epithelium (RPE) and photoreceptor cells,
causing blurred or distorted central vision. The condition can be
managed with an injection of an anti-angiogenic substance into
the eyeball, which improves the symptomatic state during the early
stages of the disease. Cell-based treatments are being developed toreplace impaired RPE with intact RPE. In these treatments, RPE is
prepared from iPSCs derived from a patient to prevent visual loss.
Themain purpose is to evaluate the safety of the iPSC-derived prod-
uct and therapeutic procedure; in addition, tumorigenesis of the
cell product is also being investigated [11]. Once the safety war-
ranty is conﬁrmed, the iPSC-derived RPE will be implanted at an
early stage of the disease for further efﬁcacy. In combination with
low vision care and rehabilitation, iPSC-based therapy will provide
better treatment for patients.
6. Chondrocyte product with scaffold
Symposium speakers went on to discuss regenerative medicine
for patients with osteoarthritis, the most common form of arthritis.
Osteoarthritis is a chronic condition in which cartilage that sup-
ports the joints breaks down and causes bone-on-bone friction.
Approximately 10 million people suffer from osteoarthritis of the
knee in Japan. As cartilage has limited regenerative capability due
to its avascular nature or lack of blood vessels, cartilage regenera-
tion is a key challenge in tissue engineering.
A Swedish group originally reported implantation of
chondrocytesda type of cell found in cartilagedafter ex vivo prop-
agation without scaffold [12]. Mitsuo Ochi's group combined chon-
drocytes with a scaffold, that is, ‘atelocollagen’ [13]. Chondrocyte/
atelocollagen was commercialized by J-TEC Inc. after a clinical trial
at Hiroshima University Hospital in April 2013, and it took 12 years
to progress from an investigative new drug application to approval
[14]. More sophisticated implantation techniques of the cell prod-
uct still need to be developed [15]. To regenerate the auricle,
nose, and chin bone, tissues or organs need to be generated.
Tsuyoshi Takato emphasized the importance of innovation of hu-
man cellular and tissue-based products with a speciﬁc shape and
stiffness [16]. By using 0.1 g of auricular cartilage, Takato and col-
leagues found that 6 cm of nasal cartilage can be successfully gener-
ated over 4 weeks' cultivation. In addition, auricles can also be
generated. The symposium speakers reafﬁrmed that one of the ﬁnal
goals of regenerative medicine is to generate products such as tis-
sues and organs, as well as cell suspension.
7. Cell sheet engineering
Using scaffolds may overcome the limitations of current tech-
niques, including single-cell suspension injection. Yoshiki Sawa dis-
cussed how he and his colleagues developed a strategy to restore
tissue functions using temperature-responsive cell culture surfaces
[17]. The use of biodegradable polymer enabled transplantable cell
sheetsmanufacturedwith temperature-responsive culture surfaces
to be used for cell delivery. Cell sheet technology is currently being
used in clinical studies for patients with otitis media, pyorrhea
alveolaris, and cardiomyopathy. In 2000, Sawa collaborated with
Teruo Okano, who originally developed temperature-responsive
culture surfaces, and began a clinical study that applied the cell
sheet technique using skeletal myocytes to a patient with cardiac
failure [18,19]. The results revealed that efﬁcacy of the skeletal myo-
cyte sheet is comparable with organ transplantation. To increase
the functionality of cell sheets, Sawa began research on cardiomyo-
cyte sheets in collaboration with Shinya Yamanaka. iPSC-derived
cardiomyocytes were found to be of an immature nature in vitro,
however, in vivo maturation was detected after implantation.
Multi-layered cell sheets are currently under development to
manufacture tissues and organs. Although single-cell sheets can
be directly implanted onto tissues or organs, multi-layered cell
sheets require vasculature. Tatsuya Shimizu and colleagues suc-
cessfully generated multi-layered cardiomyocytes with a vascular
network by adding endothelial cells [20,21]. These multi-layered
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sufﬁcient to support a failing heart. Shimizu also succeeded in
manufacturing tube-shaped beating cardiomyocyte sheets using
iPSCs as a raw material.
8. Direct reprogramming
Cellular reprogramming techniques have been implicated in
iPSC generation. Masaki Ieda et al. successfully generated beating
cardiomyocytes from murine ﬁbroblasts with three transcription
factors in vitro [22]. Direct injection of the same combination of
transcription factors into failing hearts after myocardial infarction
generated cardiomyocyte-like cells in vivo. This technique of
cellular reprogramming without iPSC generation, known as ‘direct
reprogramming’, can generate cardiomyocytes even in humans
with the addition of three more transcription factors [23]. This
fundamental ﬁnding can lead to gene therapy of the heart in com-
bination with infusion techniques via catheter.
9. Growth and development of research in the stem cell ﬁeld
The symposium reported on a publication analysis of 60,000
publications on stem cell research from 2008 to 2012 that focused
on countries' contributions to the ﬁeld, such as research output,
citation impact and collaboration activities [24]. The report found
that Harvard University completely outstripped other universities
and institutes with regard to number of publications and citations
in the ﬁeld. In terms of inﬂuence, American institutes were ranked
at the top and Kyoto University was ranked in 17th place. Regarding
the number of publications on iPSC studies, Kyoto University
ranked second next to Harvard University in ﬁrst place, and ﬁve
Japanese organizations also ranked high in the list. The review
also showed that Japanese research institutes did not collaborate
with overseas institutes as much as their American and European
counterparts, a result which underscores the need for a greater de-
gree of international collaboration in Japan in the future.
10. Collaboration of industry-government-academia research
groups and global competition
The Forum for Innovative Regenerative Medicine (FIRM) was
established to support regenerative medicine through industry-
led partnerships and to advance its commercialization in Japan
[25]. More than 100 companies including pharmaceutical com-
panies and a machinery manufacturer participate in FIRM. At the
symposium, FIRM Chairman Yuzo Toda spoke of FIRM's role to pro-
vide high-quality products for regenerative medicine that are inter-
nationally competitive. FIRM also proposes to establish a private
insurance system to realize regenerative medicine and commer-
cialize technologies, and strives to promote Japan's novel regulato-
ry system to theworld. Toda also spoke about FIRM's role to identify
challenges in the business development and industrialization of
regenerative medicine, and provide valuable advice and solutions
to academic and industry professionals.
Industrialization of technology is an essential process to return
the results of research to society. FIRM Director Shosaku Murayama
described FIRM's mission to make techniques developed in Japan
widely available through business, especially iPSC techniques. Mur-
ayama explained that collaboration between companies and
academia is necessary to resolve issues related to stability, quality
and cost of products. At present, industrialization of iPSCs is grad-
ually shifting from the pre-clinical to the clinical stage. The FIRM
speakers emphasized that developing industry-led partnerships
with governments, academia, and the private sector and building
a relationship with the media are crucial to FIRM's mission tosupport the realization of iPSC-based therapy, and to promote the
commercialization and application of new techniques using iPSCs
in Japan.
11. Concluding remarks
The symposium provided a valuable overview of important
achievements and developments in regenerative medicine,
including the ﬁrst-in-human clinical trial of iPSC-derived products.
The Society hopes that this symposiumwill lead to a clearer under-
standing of the fusion of medicine and engineering in regenerative
medicine, as well as the issues surrounding commercialization. We
also hope it will help to facilitate safe access to novel cell products
and techniques in Japan for the beneﬁt of the wider community.
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